Association Between Comorbidities and Quality of Life in Psoriatic Arthritis: Results from a Multicentric Cross-sectional Study

• Published in: Journal of rheumatology 2020-03, Vol.47 (3), p.369-376
• Main Authors: Bavière, Wallis, Deprez, Xavier, Houvenagel, Eric, Philippe, Peggy, Deken, Valerie, Flipo, Rene-Marc, Paccou, Julien
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antirheumatic Agents - therapeutic use; Anxiety - epidemiology; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - economics; Arthritis, Psoriatic - epidemiology; Biological Products - therapeutic use; Comorbidity; Cost of Illness; Cross-Sectional Studies; Female; France - epidemiology; Humans; Life Sciences; Male; Mental Health; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Self Report; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor Inhibitors - therapeutic use
• ISSN: 0315-162X; 1499-2752
• DOI: 10.3899/jrheum.181471

In psoriatic arthritis (PsA), comorbidities add to the burden of disease, which may lead to poorer quality of life. The purpose of this study was to evaluate the relationship between comorbidities and quality of life (QOL). Patients from a multicentric, cross-sectional study on comorbidities in PsA were included in the analysis. Data on comorbidities were collected and were subsequently used to compute the modified Rheumatic Disease Comorbidity Index (mRDCI). The Medical Outcomes Study Short Form-36 questionnaire physical (PCS) and mental component summary (MCS) scales were used to assess QOL. In total, 124 recruited patients fulfilled the ClASsification for Psoriatic ARthritis criteria (CASPAR): 62.1% were male; mean age and mean disease duration were 52.6 ± 12.6 years and 11.3 ± 9.6 years, respectively. The number of comorbid conditions was 2.0 ± 1.3, with 30.6% of the sample having currently or a history of 3 or more comorbidities. In the multivariate linear regression analysis, only anxiety remained significantly related to mental health (p < 0.0001). Anxiety alone accounted for 28.7% of the variance in MCS scores. Moreover, MCS was also significantly associated with the mRDCI score, which explained 4.9% of the variance in MCS [β = -1.56 (standard error 0.64), R = 0.049, p = 0.0167]. In contrast, PCS was not significantly associated either with type or number of comorbidities. In this study, the type of comorbidity appeared to have a greater effect than the number of comorbidities. Indeed, anxiety in PsA was independently associated with QOL and would thus be an important factor to take into account in daily clinical practice.